Table 1.
Baseline Characteristics (n=15)
| Age | Mean, years (SD) | 56.7 (±14.3) |
| Gender | Female, n (%) | 9 (60.0) |
| Male, n (%) | 6 (40.0) | |
| Race | White, n (%) | 10 (66.7) |
| African American, n (%) | 3 (20.0) | |
| American Indian, n (%) | 1 (6.7) | |
| No Response, n (%) | 1 (6.7) | |
| Ethnicity | Hispanic/Latino, n (%) | 2 (13.3) |
| Not Hispanic/Latino, n (%) | 13 (86.7) | |
| Weight | Mean, kg (SD) | 97.5 (±19.1) |
| BMI | Mean, kg/m2 (SD) | 34.3 (±5.3) |
| BMI category | Overweight (BMI 25-29.9), n (%) | 5 (33.3) |
| Class 1 obesity (BMI 30-34.9), n (%) | 4 (26.7) | |
| Class 2 obesity (BMI 35-39.9), n (%) | 3 (20.0) | |
| Class 3 obesity (BMI >40), n (%) | 3 (20.0) | |
| Age at diabetes diagnosis | Mean, years (SD) | 44.8 (±14.7) |
| Years elapsed since diagnosis | Mean, years (SD) | 12.0 (±6.6) |
| Most recent HgbA1C | Mean, % (SD) | 8.4 (±0.7) |
| Mean, mmol/mol (SD) | 68 (±2.2) | |
| Medicines Used | Basal Insulin, n (%) | 15 (100.0) |
| Prandial Insulin, n (%) | 12 (80.0) | |
| Metformin, n (%) | 6 (40.0) | |
| GLP-1, n (%) | 9 (60.0) | |
| SGLT2-inhibitor, n (%) | 0 (0.0) | |
| Antihypertensive, n (%) | 9 (60) | |
| Cholesterol-lowering, n (%) | 11 (73.3) | |
| Heartburn Control, n (%) | 10 (66.7) | |
| Depression/Anxiety Control, n (%) | 7 (46.7) | |
| Total Daily Insulin Dose | Mean, units/day (SD) | 90.9 (59.9) |
| Geometric mean, units/day (SD Factor) | 74 (2.0) |